Literature DB >> 19681021

Community-acquired complicated intra-abdominal infections in children hospitalized during 1995-2004 at a paediatric surgery department.

Nitza Newman1, Eman Wattad, David Greenberg, Nehama Peled, Zahavi Cohen, Eugene Leibovitz.   

Abstract

UNLABELLED: Information on the epidemiologic, clinical, microbiologic and therapeutic aspects of community-acquired complicated intra-abdominal infections in paediatrics is limited. The objectives of this study were to investigate the epidemiologic, clinical, microbiologic and therapeutic characteristics of community-acquired complicated intra-abdominal infections occurring in children aged 1 month-15 y. Medical charts and microbiology data of all children hospitalized with complicated intra-abdominal infections were retrospectively examined. Complicated intra-abdominal infections were defined as infections extending beyond the viscus of origin into the peritoneal space, with subsequent development of abscess or peritonitis. One hundred and twenty-three patients with complicated intra-abdominal infections (99/123, 80% >5 y of age) were included; 113 (92%) had complicated acute appendicitis. Twelve (10%) patients underwent computerized tomography-guided percutaneous drainage of periappendicular abscesses. The mean rate of complicated intra-abdominal infections among patients with complicated acute appendicitis was 10% without significant changes during the study years. Positive intra-abdominal cultures were recorded in 97/108 (90%) evaluable patients; 65/97 (67%) cases were characterized by mixed bacterial flora growth. One hundred and ninety pathogens (aerobes n=164, 86%; anaerobes n=26, 14%) were isolated. Escherichia coli was the most common pathogen (94 isolates, 57%). In vitro amoxicillin/clavulanate coverage of E. coli and Klebsiella spp was modest (81% and 86%, respectively). The ampicillin/gentamicin/metronidazole regimen was more appropriate in vitro than the amoxicillin/clavulanate regimen (3/80, 4% resistant pathogens compared with 8/43, 19%; p=0.02). Post-operative complications were recorded in 33/123 (27%) patients. Time until defervescence to < 37.5 degrees C was shorter in children with periappendicular abscess than in children with generalized peritonitis (6+/-4 vs 4+/-3 days; p=0.009). IN
CONCLUSION: (1) most community-acquired complicated intra-abdominal infections occurred as a result of acute appendicitis; (2) the rate of complicated intra-abdominal infections among patients with acute appendicitis was low and without significant changes during the study period; (3) E. coli was the most frequently isolated pathogen; (4) amoxicillin/clavulanate provided only partial coverage for complicated intra-abdominal infection pathogens and should be used with caution in the empiric treatment of complicated intra-abdominal infections.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19681021     DOI: 10.1080/00365540903159261

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  3 in total

1.  Delineation of the role of Toll-like receptor signaling during peritonitis by a gradually growing pathogenic Escherichia coli.

Authors:  Cornelis van 't Veer; Petra S van den Pangaart; Daniëlle Kruijswijk; Sandrine Florquin; Alex F de Vos; Tom van der Poll
Journal:  J Biol Chem       Date:  2011-06-20       Impact factor: 5.157

2.  Population Pharmacokinetic Modeling and Probability of Pharmacodynamic Target Attainment for Ceftazidime-Avibactam in Pediatric Patients Aged 3 Months and Older.

Authors:  Richard C Franzese; Lynn McFadyen; Kenny J Watson; Todd Riccobene; Timothy J Carrothers; Manoli Vourvahis; Phylinda L S Chan; Susan Raber; John S Bradley; Mark Lovern
Journal:  Clin Pharmacol Ther       Date:  2021-11-22       Impact factor: 6.903

3.  A comparison of blood stream infections with extended spectrum beta-lactamase-producing and non-producing Klebsiella pneumoniae in pediatric patients.

Authors:  Sevgen Tanır Basaranoglu; Yasemin Ozsurekci; Kubra Aykac; Eda Karadag Oncel; Asiye Bıcakcigil; Banu Sancak; Ali Bulent Cengiz; Ates Kara; Mehmet Ceyhan
Journal:  Ital J Pediatr       Date:  2017-09-12       Impact factor: 2.638

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.